Luo Fang, Annane Djillali, Orlikowski David, He Li, Yang Mi, Zhou Muke, Liu Guan J
Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Cochrane Database Syst Rev. 2017 Dec 4;12(12):CD008380. doi: 10.1002/14651858.CD008380.pub2.
Acute respiratory failure is a common life-threatening complication of acute onset neuromuscular diseases, and may exacerbate chronic hypoventilation in patients with neuromuscular disease or chest wall disorders. Standard management includes oxygen supplementation, physiotherapy, cough assistance, and, whenever needed, antibiotics and intermittent positive pressure ventilation. Non-invasive mechanical ventilation (NIV) via nasal, buccal or full-face devices has become routine practice in many centres.
The primary objective of this review was to compare the efficacy of non-invasive ventilation with invasive ventilation in improving short-term survival in acute respiratory failure in people with neuromuscular disease and chest wall disorders. The secondary objectives were to compare the effects of NIV with those of invasive mechanical ventilation on improvement in arterial blood gas after 24 hours and lung function measurements after one month, incidence of barotrauma and ventilator-associated pneumonia, duration of mechanical ventilation, length of stay in the intensive care unit and length of hospital stay.
We searched the following databases on 11 September 2017: the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE and Embase. We also searched conference proceedings and clinical trials registries.
We planned to include randomised or quasi-randomised trials with or without blinding. We planned to include trials performed in children or adults with acute onset neuromuscular diseases or chronic neuromuscular disease or chest wall disorders presenting with acute respiratory failure that compared the benefits and risks of invasive ventilation versus NIV.
Two review authors reviewed searches and independently selected studies for assessment. We planned to follow standard Cochrane methodology for data collection and analysis.
We did not identify any trials eligible for inclusion in the review.
AUTHORS' CONCLUSIONS: Acute respiratory failure is a life-threatening complication of acute onset neuromuscular disease and of chronic neuromuscular disease and chest wall disorders. We found no randomised trials on which to elaborate evidence-based practice for the use of non-invasive versus invasive mechanical ventilation. For researchers, there is a need to design and conduct new randomised trials to compare NIV with invasive ventilation in acute neuromuscular respiratory failure. These trials should anticipate variations in treatment responses according to disease condition (acute onset versus acute exacerbation on chronic neuromuscular diseases) and according to the presence or absence of bulbar dysfunction.
急性呼吸衰竭是急性起病的神经肌肉疾病常见的危及生命的并发症,可能会加重神经肌肉疾病或胸壁疾病患者的慢性通气不足。标准治疗包括吸氧、物理治疗、咳嗽辅助,必要时使用抗生素和间歇正压通气。通过鼻罩、颊罩或全面罩装置进行的无创机械通气(NIV)在许多中心已成为常规治疗手段。
本综述的主要目的是比较无创通气与有创通气在改善神经肌肉疾病和胸壁疾病患者急性呼吸衰竭短期生存率方面的疗效。次要目的是比较无创通气与有创机械通气对24小时后动脉血气改善情况、1个月后肺功能测量结果、气压伤和呼吸机相关性肺炎发生率、机械通气持续时间、重症监护病房住院时间和住院总时间的影响。
我们于2017年9月11日检索了以下数据库:Cochrane神经肌肉专业注册库、CENTRAL、MEDLINE和Embase。我们还检索了会议论文集和临床试验注册库。
我们计划纳入有或无盲法的随机或半随机试验。我们计划纳入在患有急性起病神经肌肉疾病、慢性神经肌肉疾病或胸壁疾病并伴有急性呼吸衰竭的儿童或成人中进行的试验,这些试验比较了有创通气与无创通气的益处和风险。
两名综述作者对检索结果进行审查,并独立选择研究进行评估。我们计划遵循Cochrane标准方法进行数据收集和分析。
我们未识别出任何符合纳入本综述标准的试验。
急性呼吸衰竭是急性起病神经肌肉疾病以及慢性神经肌肉疾病和胸壁疾病的危及生命的并发症。我们未找到可用于阐述无创与有创机械通气循证实践的随机试验。对于研究人员而言,有必要设计并开展新的随机试验,以比较无创通气与有创通气在急性神经肌肉呼吸衰竭中的效果。这些试验应考虑到根据疾病状况(急性起病与慢性神经肌肉疾病急性加重)以及是否存在延髓功能障碍而产生的治疗反应差异。